2022 Symposium Topics:

  • NET Models
  • Genetics
  • Tumor Microenvironment and Immunology 
  • NET Models Consortium
  • Tumor Biology and Rare NETS
  • Clinical and Theranostic Studies


Dawn Quelle, PhD
University of Iowa

Justin Annes, MD
PhD, Stanford University

  1. Patient Derived Tumor Organoid Models Reveal Druggable Growth Dependencies in Neuroendocrine Cancer
    Talya Dayton, PhD, Barcelona European Molecular Biology Laboratory
  2. Mechanisms, Models, and Treatments for Neuroendocrine Tumors
    James Bibb, PhD, University of Alabama at Birmingham
  3. Improving SBNET Therapy by Targeting Serotonin Metabolism
    Po Hien Ear, PhD, The University of Iowa
  4. Validation of Pheochromocytoma Organoid Models
    Patricia Dahia, MD, PhD and Alice Soragni, PhD, University of Texas Health Science Center at San Antonio/University of California, Los Angeles

SESSION 2: Genetics

Ramesh Shivdasani, MD, PhD
Dana-Farber Cancer Institute

Carl Gay, MD, PhD
University of Texas, MD Anderson Cancer Center

  1. Immunophenotypic and Molecular Characterization of Pancreatic Neuroendocrine Tumors Producing Serotonin
    Jérôme Cros, MD, PhD, University of Paris
  2. Genomic and Epigenomic Analyses of Multifocal Ileal Neuroendocrine Tumors
    Netta Makinen, PhD and Matt Meyerson, MD, PhD, Dana-Farber Cancer Institute
  3. Characterising Aggressive Pulmonary Carcinoids Through Integrative Omics Analysis Within the lungNENomics Project
    Matthieu Foll, PhD and Lynette Fernandez-Cuesta, PhD, International Agency for Research on Cancer
  4. Regulatory Heterogeneity of Neuroendocrine Tumors
    Yotam Drier, PhD, Hebrew University of Jerusalem
  5. Developmental Lineages and Mediators of Metastasis in PNETs at Single-Cell Resolution
    William Hwang, MD, PhD and Carina Shiau, BA, Massachusetts General Hospital

SESSION 3: Tumor Microenvironment and Immunology

Daniel M.Halperin, MD
University of Texas, MD Anderson Cancer Center

Matt Kulke, MD
Boston Medical Center

  1. Vascular Regulation of Liver Metastasis in Pancreatic Neuroendocrine Tumors
    Minah Kim, PhD, Columbia University Medical Center
  2. Ex vivo Expansion of TILs from panNET Liver Metastasis: In Search of Novel Adoptive Transfer Strategies for the Treatment of NETs
    Mauro Cives, MD, University of Bari Aldo Moro (Università degli Studi di Bari Aldo Moro)
  3. The 3rd Generation of CDH17CAR T Cells Eliminate NETs and GI-solid Tumors via Enhancing Multiple T Cell Signaling Pathways
    Xianxin Hua, MD, PhD, The Trustees of the University of Pennsylvania
  4. CDK4/6-MEK Targeted Therapy Causes Regression and Reduced Metastatic Colonization of Pancreatic Neuroendocrine Tumors
    Dawn Quelle, PhD, The University of Iowa
  5. The Role of the B7x Signaling Pathway in the Development and Progression of Neuroendocrine Tumors
    Ziqiang Yuan, MD and Steve Libutti, MD, Rutgers, The State University of New Jersey-RBHS-CINJ

SPECIAL SESSION: NET Models Consortium

Dawn Quelle, PhD
University of Iowa

Justin Annes, MD, PhD
Stanford University

  1. Short Presentations: NET Cell Lines, Organoids and Mice

SESSION 4: Tumor Biology and Rate NETS

Chrissie Thirlwell, MBBS, PhD University of Exeter Medical School

James Bibb, PhD
University of Alabama-Birmingham

  1. Insights into Intestinal NETs from an In Vitro Model of Human EEC Differentiation
    Pratik Singh, PhD and Ramesh Shivdasani, MD, PhD, Dana-Farber Cancer Institute
  2. Human and Murine Single-nucleus RNA-seq (snRNA-seq) Reveals Potential Mechanisms of TMEM127-mediated Susceptibility to Pheochromocytomas
    Qianjin Guo, PhD and Patricia Dahia, MD, PhD, University of Texas Health Science Center at San Antonio
    (UT Health San Antonio)
  3. Mesenteric Fibrosis in Small Intestinal Neuroendocrine Tumours
    Martyn Caplin, DM, FRCP, Maria C. Martins, Harry Hodgetts, UCL Institute for Liver and Digestive Health
  4. The Role of CCL2 and IL-8 in the Microenvironment of Pituitary Neuroendocrine Tumors
    Pedro Marques, MD, PhD, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE
  5. Defining Distinct Molecular Subtypes of High-grade Neuroendocrine Carcinomas to Predict Therapeutic Vulnerabilities
    Allison Stewart, PhD and Carl Gay, MD, PhD, University of Texas M.D. Anderson Cancer Center
  6. All-Trans Retinoic Acid Radiosensitizes Neuroendocrine Tumor Cells via Peptidyl-prolylcis-trans isomerase 1 Inhibition
    Xavier Keutgen, MD, The University of Chicago

SESSION 5: Clinical and Theranostic Studies

George Fisher, MD
Stanford University

Lisa Bodei, MD, PhD
Memorial Sloan Kettering Cancer Center

  1. Digital Image Analysis in Prediction of Metastatic Midgut and Pancreatic NET Outcomes
    Stephen Ward, MD, PhD and Michelle Kim, MD, PhD, Cleveland Clinic
  2. Transcriptomic Influences of Racial Disparities in Pancreatic Neuroendocrine Tumors
    Brendan Herring, MS and Bart Rose, MD, University of Alabama at Birmingham School of Medicine
  3. A Closer Look: Fluorescent Analogs of Clinical Stage PRRT Agents Reveal Specific Binding to Multipotent Bone Marrow Stem Cells
    Susanne Kossatz, PhD, Technical University Munich
  4. Pb-203 Image-Guided Pb-212 Receptor Targeted Alpha-Particle Therapy for NETs –An Emerging Paradigm
    Michael Schultz, PhD, The University of Iowa
  5. The Wnt Pathway Protein Dvl1 Targets Sstr2 for Lysosome-dependent Degradation
    Jeffrey Frost, PhD, The University of Texas Health Science Center at Houston
  6. uPAR-PET in Neuroendocrine Tumor Patients: Final Results from a Prospective Phase II Trial and its Implications for uPAR-targeted Radionuclide Therapy
    Andreas Kjaer, PhD, University of Copenhagen